Amneal Pharmaceuticals (AMRX) announced the FDA has approved the company’s cyclosporine ophthalmic emulsion 0.05%, a sterile, preservative-free formulation supplied in single-use vials. The product is the generic equivalent of Restasis 0.05%, a registered trademark of Allergan, an AbbVie (ABBV) company.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMRX:
- Amneal Pharmaceuticals announces FDA approval for iohexol injection
- Amneal Pharmaceuticals Reports Strong Q3 Growth Amid Challenges
- Amneal Pharmaceuticals price target raised to $13 from $11 at Piper Sandler
- Amneal Pharmaceuticals Reports Strong Q3 2025 Results
- Amneal Pharmaceuticals reports Q3 adjusted EPS 17c, consensus 14c